Global Novel Vaccine Delivery Devices Industry Report 2019-2030

News provided by

Jan 03, 2020, 09:15 ET

DUBLIN, Jan. 3, 2020 /PRNewswire/ -- The "Novel Vaccine Delivery Devices Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Novel Vaccine Delivery Devices Market, 2019-2030

features an extensive study of the current landscape and the likely future opportunities associated with novel vaccine delivery devices, over the next 10-12 years.

One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for novel vaccine delivery devices. Based on various parameters, such as number of marketed / pipeline products, price of devices (for commercially available products only) and estimated annual adoption rate, we have developed an informed estimate on the likely evolution of the market over the period 2019-2030.

In addition, we have provided the likely distribution of the current and forecasted opportunities across:

[A] type of device (electroporation-based needle free injection systems, oral delivery systems, nasal delivery systems, jet injectors, microneedle patches and microinjectors)
[B] route of administration (oral, intramuscular, intranasal, intradermal and subcutaneous)
[C] type of vaccine (Bivalent Oral Polio Vaccine, BCG Vaccine, DTP-HepB-Hib Vaccine, Pneumococcal Conjugate Vaccine, Influenza Vaccine, Measles Vaccine, Tetanus-Diphtheria Vaccine and Others)
[D] key geographical regions (North America, Europe, Asia and rest of the world)

According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025.

Recent global immunization records indicate that more than 115 million children were immunized against diphtheria, tetanus and pertussis in 2018. Given the rate at which the global population is growing, the demand for vaccines is likely to increase significantly.

However, biopharmaceutical developers are plagued by concerns related to storage and handling of such preventive / therapeutic products. One commonly reported issue is related to vaccine administration. Despite the success of conventional delivery approaches, which rely on the intramuscular and subcutaneous routes of administration, the present scenario dictates that further improvements are required in order to deal with challenges related to large scale immunization initiatives. Some of the commonly reported disadvantages of the conventional (parenteral) mode of delivery include pain during administration, risk of cross contamination, needlestick injuries, and inaccurate dosing.

Of late, there has been an evident shift in interest to non-invasive immunization methods, which include oral, intranasal and transdermal modes of administration. Currently, many biopharmaceutical companies and clinical research institutes are engaged in the development of novel vaccine delivery systems, taking into consideration the specific requirements of large scale immunization initiatives. As a result, significant efforts have been put into the development of drug delivery technologies / devices, such as microneedle patches, electroporation-based needle free injection systems, jet injectors, inhalation-based delivery systems, biodegradable implants and certain novel types of oral delivery systems.

It is worth highlighting that most of the aforementioned systems are specifically being designed to facilitate pain-free administration of vaccines and allow self-administration. Vaccine developers are also attempting to devise ways to make such products more stable so as to eliminate the need for cold chain in transporting such products. Given the pace of innovation in this field, it is anticipated that the novel vaccine delivery devices market is likely to witness radical changes in the coming years.

Amongst other elements, the report includes:

A detailed assessment of the overall novel vaccine delivery devices market landscape, featuring an elaborate list of device developers and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, type of device (autoinjectors, microneedle patches, jet injectors, dry powder inhalers, microinjectors, nasal delivery systems, pen injectors, biodegradable implants, electroporation-based needle free injection systems and novel oral delivery systems), route of administration (subcutaneous, transdermal, intramuscular, intradermal, inhalation, intranasal, and oral), drug delivery mechanism (mechanical, electrical and miscellaneous), nature of vaccine administration (invasive and non-invasive), speed of administration (fast, moderate and slow), self- administration potential, provisions for audio / visual feedback, device usability (disposable and reusable), type of needle (needleless, fixed needle, detachable needle, and hidden needle), and current development status of novel vaccine delivery systems (preclinical / discovery, clinical and marketed).
A detailed competitiveness analysis of novel vaccine delivery devices, taking into consideration the supplier power (based on the year of establishment of developer company) and key product specifications (such as route of administration, device usability, drug delivery mechanism, availability of needle safety system, speed of administration, self-administration potential, provisions for audio / visual feedback, nature of administration, cold chain requirement and current status of development).
An analysis evaluating the effectiveness of various vaccines delivery devices in order to compare their respective strengths and capabilities based on a variety of relevant parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.
A detailed list of marketed and pipeline vaccine candidates that are anticipated to be developed in combination with novel vaccine delivery devices in the near future, featuring analysis based on parameters, such as type of active ingredient, dosage form, route of administration, target disease indication and target patient population.
Elaborate profiles of prominent product developers engaged in this domain; each profile features a brief overview of the company, its financial information (if available), information on its product portfolio, recent developments and an informed future outlook.
An analysis of recent collaborations and partnership agreements inked in this domain since 2014, including details of deals that were / are focused on novel vaccine delivery devices. The partnerships captured in the report were analyzed on the basis of year of establishment, type of agreement, type of device, type of vaccine, type of active ingredient and target disease indication.
A discussion on important, industry-specific trends, key market drivers and challenges, under a comprehensive SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders:

Michael Schrader, Chief Executive Officer and Founder, Vaxess Technologies
Mikael Ekstrom and Roger Lassing, Vice President, Business Development, Iconovo
Henry King, Market Intelligence and Business Development Manager, Innoture

Key Topics Covered

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Vaccines
3.2.1. Classification of Vaccines
3.2.2. Key Components of a Vaccine Formulation
3.2.3. Expression Systems Used for Vaccine Production
3.3. Vaccine Delivery
3.3.1. Intradermal Route
3.3.2. Subcutaneous Route
3.3.3. Intramuscular Route
3.3.4. Oral Route
3.3.5. Intranasal Route
3.3.6. Inhalation Route
3.4. Key Challenges Associated with Vaccine Delivery
3.5. Novel Approaches for Vaccine Delivery
3.5.1. Autoinjectors
3.5.2. Biodegradable Implants
3.5.3. Buccal / Sublingual Vaccine Delivery Systems
3.5.4. Electroporation-based Needle Free Injection Systems
3.5.5. Inhalation / Pulmonary Vaccine Delivery Systems
3.5.6. Jet Injectors
3.5.7. Microinjection System
3.5.8. Novel Orally Administrable Formulations
3.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Marketed Vaccines Landscape
4.3. Clinical-Stage Vaccines Landscape
4.4. Novel Vaccine Delivery Devices: Overall Market Landscape
4.4.1. Analysis by Type of Device
4.4.2. Analysis by Route of Administration
4.4.3. Analysis by Drug Delivery Mechanism
4.4.4. Analysis by Nature of Vaccine Administration
4.4.5. Analysis by Speed of Vaccine Administration
4.4.6. Analysis by Self-Administration Potential
4.4.7. Analysis by Availability of Audio / Visual Feedback
4.4.8. Analysis by Device Usability
4.4.9. Analysis by Type of Needle
4.4.10. Analysis by Stage of Development
4.5. Novel Vaccine Delivery Device Developers: Overall Market Landscape
4.5.1. Analysis by Type of Developer
4.5.2. Analysis by Year of Establishment
4.5.3. Analysis by Company Size
4.54. Analysis by Geographical Location

5. DEVICE COMPETITIVENESS ANALYSIS
5.1. Chapter overview
5.2. Assumptions and Methodology
5.3. Novel Vaccine Delivery Devices: Competitive Landscape
5.4. Concluding Remarks

6. TECHNOLOGY EFFECTIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Vaccine Delivery Devices: Technology Effectiveness Analysis
6.4.1. Devices for Marketed Vaccines
6.4.2. Devices for Clinical-Stage Vaccines

7. NOVEL VACCINE DELIVERY DEVICES: LIKELY VACCINE CANDIDATES
7.1. Chapter Overview
7.2. Marketed Vaccines
7.2.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
7.2.2. Jet Injectors: Likely Vaccine Candidates
7.2.3. Microneedle Patches: Likely Vaccine Candidates
7.2.4. Nasal Delivery Systems: Likely Vaccine Candidates
7.2.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.2.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.2.7. Prefilled Syringes: Likely Vaccine Candidates
7.3. Clinical-Stage Vaccines
7.3.1. Electroporation-based Needle Free Injection Systems: Likely Vaccine Candidates
7.3.2. Jet Injectors: Likely Vaccine Candidates
7.3.3. Microneedle Patches: Likely Vaccine Candidates
7.3.4. Nasal Delivery Systems: Likely Vaccine Candidates
7.3.5. Oral Delivery Systems for Liquid Formulations: Likely Vaccine Candidates
7.3.6. Oral Delivery Systems for Solid Formulations: Likely Vaccine Candidates
7.3.7. Prefilled Syringes: Likely Vaccine Candidates

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. 3M
8.3. Becton Dickinson
8.4. Consort Medical
8.5. D'Antonio Consultants International
8.6. Enesi Pharma
8.7. Ichor Medical
8.8. Iconovo
8.9. Inovio Pharmaceuticals
8.10. PharmaJet
8.11. Union Medico

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Vaccine Delivery Devices: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Device
9.3.4. Analysis by Type of Partnership and Type of Device
9.3.5. Analysis by Type of Vaccine and Type of Device
9.3.6. Analysis by Type of Active Ingredient
9.3.7. Analysis by Target Disease Indication
9.3.8. Popular Vaccine Delivery Devices: Analysis by Number of Partnerships
9.3.9. Most Active Industry Players: Analysis by Number of Partnerships
9.3.10. Geographical Analysis

10. SWOT ANALYSIS
10.1. Chapter Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats
10.6. Concluding Remarks

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Novel Vaccine Delivery Devices Market, 2019-2030
11.4. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Device, 2019-2030
11.5. Global Novel Vaccine Delivery Devices Market: Distribution by Route of Administration, 2019-2030
11.6. Global Novel Vaccine Delivery Devices Market: Distribution by Type of Vaccine, 2019-2030
11.7. Global Novel Vaccine Delivery Devices Market: Distribution by Regions, 2019-2030
11.7.1. Novel Vaccine Delivery Devices Market in North America, 2019-2030
11.7.2. Novel Vaccine Delivery Devices Market in Europe, 2019-2030
11.7.3. Novel Vaccine Delivery Devices Market in Asia Pacific, 2019-2030
11.7.4. Novel Vaccine Delivery Devices Market in Rest of the World, 2019-2030

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Vaxess Technologies
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Michael Schrader, Chief Executive Officer and Founder
12.3. Iconovo
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Mikael Ekstrom and Roger Lassing, Vice Presidents, Business Development
12.3. Innoture
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Henry King, Market Intelligence and Business Development Manager

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

3M
Abbott
AbCellera
ABO Pharmaceuticals
AC Immune
Accelovance
AdminMed
Aduro Biotech
Advagene Biopharma
Advaxis
Aelix Therapeutics
Aeras
Aesica Pharmaceuticals
Affinivax
Affiris
Agenus
AgResearch
Aimmune Therapeutics
Aivita Biomedical
AJ Vaccines
Aktiv-Dry
Alopexx Vaccine
AlphaVax
Altimmune
American Association for Cancer Research
Anhui Zhifei Longcom Biologic Pharmacy
Animal Health Board
Antares Pharma
Apogee Technology
Araclon Biotech
Archivel Farma
Argos Therapeutics
Astellas Pharma
AstraZeneca
Australian Respiratory and Sleep Medicine Institute
AVIR Green Hills Biotechnology
Axon Neuroscience
Barr Labs
Battelle
Bavarian Nordic
Baylor College of Medicine
BCN Peptides
Becton Dickinson
Beijing Center for Disease Control and Prevention
Beijing Institute of Biological Products
Beijing Minhai Biotechnology
Beijing Tricision Biotherapeutics
Beijing Wantai Biological Pharmacy Enterprise
Beijing Zhifei Lvzhu Biopharmaceutical
Bernhard Nocht Institute for Tropical Medicine
Bharat Biotech International
Bill and Melinda Gates Foundation
Bilthoven Biologicals
Biofabri
Bioject Medical Technologies
Biological E
Bio-Manguinhos
Biomedical Advanced Research and Development Authority
Biomedizinische Forschungs
BioNTech
BiondVax Pharmaceuticals
Bioneedle Technologies Group
Biontech
BioSerenTach
Birla Institute of Technology and Science
Boehringer Ingelheim
Boryung Pharmaceutical
BrightPath Biotherapeutics
Bristol-Myers Squibb
Bul Bio-National Center of Infectious and Parasitic Diseases
Cadila Health Care
Cancer Insight
Cancer Research UK
Cancer Vaccines Charitable Trust
CanSino Biologics
Capital Medical University
Celerion
Celgene
Celldex Therapeutics
Centers for Disease Control and Prevention
Center for Genetic Engineering and Biotechnology
Center for HIV/AIDS Vaccine Immunology (CHAVI)
Changhai Hospital
Charite University
Chengdu Institute of Biological Products
Children's Hospital of Philadelphia
Chinese PLA General Hospital
Chiron Behring Vaccines
Chumakov Federal Scientific Center for Research & Development of Immune-And Biological Products
City of Hope Medical Center
College of Medicine and Allied Health Sciences
Consort Medical
Corium
CosMED Pharmaceutical
Cromos Pharma
CSL
CureVac
Curevo
DALI Medical Devices
Dana-Farber Cancer Institute
D'Antonio Consultants International
Dartmouth-Hitchcock Medical Center
Debiotech
Department of Health and Human Services
Duke University
Dutch Cancer Society
Dynavax Technologies
E Ink Holdings
E3D Elcam Drug Delivery Devices
Earle A. Chiles Research Institute
Elios Therapeutics
Emergent BioSolutions
Emergent Product Development
EMMES
Emory University
Enesi Pharma
EuBiologics
Federal State Budgetary Scientific Institution
FFF Enterprises
FHI 360
FIT Biotech
Flextronics International
Flinders University
FluGen
Forschungszentrum Jlich
Fourth Military Medical University
Fred Hutchinson Cancer Research Center
Fuda Cancer Hospital
FUJIFILM Pharmaceuticals
Gamaleya Research Institute of Epidemiology and Microbiology
GC Pharma
Genentech
GeneOne Life Science
Genetic Immunity
Genexine
Genocea Biosciences
Georgia Institute of Technology
GeoVax
German Cancer Research Center
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GPO-MBP
Gradalis
Grameen Foundation
Green Cross
GreenSignal Bio Pharma
Gritstone Oncology
Guangdong 999 Brain Hospital
Guangzhou Anjie Biomedical Technology
Guangzhou Trinomab Biotech
Gynecologic Oncology Group
H. Lee Moffitt Cancer Center and Research Institute
Hadassah Medical Organization
Haffkine Bio Pharmaceutical
Hemispherx Biopharma
HIV Vaccine Trials Network
Hookipa Biotech
Hoosier Cancer Research Network
Hualan Biological Bacterin
Ichor Medical Systems
Iconovo
IDRI
Il-Yang Pharmaceutical
Immatics
Immune Biosolutions
Immune Design
Immunitor
ImmunoCellular Therapeutics
Immunomic Therapeutics
ImmuPatch
Imperial College London
Imugene
INCYTO
Infectious Disease Research Institute
Innoture Medical Technology
Inovio Pharmaceuticals
Inserm
Institut Pasteur
Institute of Clinical Research
Institute of Vaccines and Medical Biologicals
International Centre for Diarrheal Disease Research
International Vaccine Institute
Intravacc
Invectys
IPPOX Foundation
ISA Pharmaceuticals
Istari Oncology
Janssen Biotech
Japan BCG Laboratory
Jiangsu Jindike Biotechnology
Jiangsu Province Centers for Disease Control and Prevention
Jinan University Guangzhou
JN-International Medical
Johns Hopkins Bloomberg School of Public Health
Jonsson Comprehensive Cancer Center
Jurong Centers for Disease Control and Prevention
Kenya Medical Research Institute
Korean Center for Disease Control and Prevention
Kurve Technology
Laboratory Corporation of America
Leiden University Medical Center
Leidos
LG Chem
Likang Life Sciences
LimmaTech Biologics
London School of Hygiene and Tropical Medicine
Louisiana State University Health Sciences Center in New Orleans
LTS
Ludwig Institute for Cancer Research
Ludwig-Maximilians-University, Charite University
LuMind Research Down Syndrome Foundation
Madison Vaccines
Mahidol University
Marker Therapeutics
Massachusetts General Hospital
MassBiologics
Mayo Clinic
MCM Vaccine
McMaster University
MD Anderson Cancer Center
Medicago
Medical International Technologies
Medical Research Council
Medical University Innsbruck
Medical University of Vienna
Medigen Vaccine Biologics
MedImmune
MEDRx
MedsForAll
Memorial Sloan Kettering Cancer Center
Mercia Pharma
Merck
Microdermics
Micron Biomedical
Micropoint Technologies
MIKROGEN
Military Infectious Diseases Research Program
Minervax
Ministry of Health of the Russian Federation
Ministry of Health and Sanitation of Sierra Leone
Moffitt Clinical Research Network
Mogam Biotechnology Research Institute
Moore Medical
MSD Wellcome Trust Hilleman Laboratories
Mundipharma
Mylan
NanoPass Technologies
NantKwest
National Cancer Institute
National Institute for Health Research
National Institute for Medical Research
National Institute of Allergy and Infectious Diseases
National Institute of Biomedical Imaging and Bioengineering
National Institute on Aging
National Institutes of Health
National Pediatric Cancer Foundation
National University Hospital
Naval Medical Research Center
Nemaura Pharma
Nemera
Neon Therapeutics
Norwegian Institute of Public Health
Nova Immunotherapeutics
Nova Laboratories
Novartis
Novavax
NovInject
Nuance Designs
OncBioMune Pharmaceuticals
OncoPep
OncoTherapy Science
Oncovir
Olymvax Biopharmaceuticals
OptiNose
Organon Teknika
Osaka University
Ospedale San Raffaele
Oswaldo Cruz Foundation
Panacea
Parexel
PATH
PepTcell
Pfizer
PharmaJet
PHC Injection Device Technologies
Philipps University Marburg Medical Center
Philips Medisize
Picofluidics
Plumbline Life Sciences
Profectus BioSciences
Prometheon Pharma
PROSENEX Ambulatoriumbetriebs
Proswell Medical
Protein Sciences
Providence Cancer Center
Providence Health & Services
PT Bio Farma
Public Health England (PHE)
Queen's University Belfast
Research Foundation for Microbial Diseases of Osaka University
Rising Tide Foundation
Robbins Instruments
Robert Koch Institut
Romagnolo Scientific Institute for the Study and Treatment of Tumors
Roswell Park Cancer Institute
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Russian Academy of Sciences
Sanaria
Sanofi
Scandinavian Biopharma
Sellas Life Sciences Group
Sementis
Seqirus
Serum Institute of India
Shanghai Bovax Biotechnology
Shanghai Houchao Biotechnology
Shantha Biotechnics
Shenzhen Geno-Immune Medical Institute
Shin Nippon Biomedical Laboratories
SHL Group
Sidney Kimmel Comprehensive Cancer Center
Sinovac Biotech
SK Bioscience
Skinject
Stand Up To Cancer
Stanford University
Statens Serum Institut
Stevanato Group
Swiss Group for Clinical Cancer Research
Takeda
Task Foundation
Teva Pharmaceutical
Texas Children's Hospital
The Aurum Institute
The Clatterbridge Cancer Center
The First Affiliated Hospital of Guangdong Pharmaceutical University
The Immunobiological Technology Institute
The Methodist Hospital System
The Wistar Institute
Themis Bioscience
TheraJect
Third Military Medical University
Transgene
Treos Bio
Trudell Medical International
TuBerculosis Vaccine Initiative
UbiVac
Union Medico
United States Agency for International Development
United States Army Medical Research Institute of Infectious Diseases
United States Department of Defense
University Health Network
University Hospital Tuebingen
University Medical Center Hamburg-Eppendorf
University Medical Center Groningen
University of Arkansas
University of California
University of Cape Town Lung Institute
University of Cologne
University of Copenhagen
University of Florida
University of Groningen
University of Iowa
University of Lausanne Hospitals
University of Liverpool
University of Maryland
University of Michigan
University of Oxford
University of Pennsylvania
University of Pisa
University of Pittsburgh
University of South Australia
University of Southampton
University of Sydney
University of Washington
University of Wisconsin
University of Zaragoza
US Army Medical Research and Material Command
Vaccibody
Vaccitech
Valeritas
Valneva
Vaxart
Vaxess Technologies
VAXIMM
Vaxine
Vaxxas
VBI Vaccines
Vetter Pharma
ViciniVax
ViroStatics
Walter Reed Army Institute of Research
Washington University School of Medicine
Weill Medical College of Cornell University
West Pharmaceuticals
World Health Organization
World Vision of Ireland
Wyeth Pharmaceuticals
XEME Biopharma
Xiamen Innovax Biotech
Xiamen University
Ypsomed
Zosano Pharma

For more information about this report visit https://www.researchandmarkets.com/r/vh9rj8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets